ContraVir begins pharmacokinetic study of FV-100 for treating shingles

Dec 9 2014

ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development.

FV-100 is a fast acting, low dose, once-daily oral antiviral agent being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus. In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain, known as post-herpetic neuralgia, or PHN.

James Sapirstein, Chief Executive Officer of ContraVir, commented, "Initiation of this PK study strongly aligns with our goal of optimizing the treatment regimen for FV-100. We look forward to reporting the results of this study in 2015, and to accelerating our plans to begin dosing shingles patients in the next clinical efficacy trial."

In addition to the current PK trial, ContraVir has completed planning a larger clinical study of FV-100 to confirm the previous favorable efficacy and safety results. The study is designed to measure the efficacy of FV-100 for treating Shingles and associated PHN, as measured by the incidence of clinically meaningful pain at the end of the follow-up period, as well as determine the best dose and regimen of treatment.

SOURCE ContraVir Pharmaceuticals, Inc.